Skip to Content Skip to Search

GSK study showed targeted therapy combination achieved 14 month overall survival in patients with advanced breast cancer

London UK, Philadelphia, PA – In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in ErbB2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 – 13).

EMBARGOED Until:  December 11, 2009 (12:30pm CST)

London UK, Philadelphia, PA – In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in ErbB2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 – 13).

The study included 296 women with a type of breast cancer known as ErbB2-positive disease, characterized by an overexpression of the ErbB2 protein in the cancer cells.  Patients enrolled in the study experienced recurrence of breast cancer despite a median of three prior trastuzumab-based therapies. The data presented at the San Antonio congress showed that patients overcame resistance to trastuzumab with the introduction of the lapatinib-trastuzumab combination.

“The clinical benefits brought forth by the lapatinib and trastuzumab combination are quite compelling and lead me to believe the agents may be acting together to form a sort of ‘dual blockade’ to obstruct the ErbB2 pathway necessary for the tumour to thrive,” said primary investigator, Kimberly Blackwell, M.D., Duke University Medical Center.

Patients in the study were randomized to receive single agent lapatinib (1500 mg/daily) or a combination of lapatinib (1000 mg p.o. daily) plus trastuzumab (2 mg/kg).  For those patients treated with monotherapy lapatinib, cross-over to the combination was allowed if the disease progressed after at least four weeks of therapy. Final analysis showed clinical activity for lapatinib in the control arm.  Women treated with monotherapy lapatinib experienced a median overall survival of 9.5 months compared with 14 months when treated with the combination (median HR: 0.74, p=0.026).

“It’s possible that, by lapatinib working inside the cell and trastuzumab working outside the cell, the combination of agents is able to provide a more complete anti-tumour attack,” said Blackwell.  “To achieve a survival advantage of greater than one year for this aggressive form of breast cancer is very encouraging.” 

Final safety analysis showed the incidence of adverse events were similar among both treatment groups with the exception of the incidence of grade 1 and 2 diarrhoea, which was significantly higher in the combination group (P = 0.03).  The incidence of grade 3 or higher AEs was similar among treatment groups (7%).The most common adverse events (incidence =10%) were diarrhoea, nausea, rash, fatigue and vomiting.  Of the Grade 3/4 adverse events observed, cardiac events were reported in three patients on the combination arm and in one patient on the monotherapy arm.  One patient in the combination arm experienced cardiac failure and later died due to pulmonary thromboembolism that was caused by disease progression and/or study medication.

“Very few clinical studies have shown a survival benefit in metastatic breast cancer,” said Steven Stein, M.D., Vice President, Medicine Development, GSK Oncology.  “It’s very encouraging to see the results gained by combining these two agents.” 

TYKERB is currently indicated in combination with Xeloda® (capecitabine) for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress ErbB2 and who have received prior therapy including an anthracycline, a taxane, and Herceptin (trastuzumab). TYKERB alone or in combination with HERCEPTIN is not approved in this setting.

GSK in Oncology

GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients.  Through GSK’s revolutionary ‘bench to bedside’ approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector.  Our worldwide research in oncology includes collaborations with more than 160 cancer centres. GSK is closing in on cancer from all sides with a new generation of patient focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.  For more information about GSK Oncology, visit www.gskoncology.com.

About GlaxoSmithKline

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For company information, visit GlaxoSmithKline at www.gsk.com.

To access the latest GSK news, visit http://us.gsk.com.

Notes to Editors:

TYKERB® is a registered trademark of the GlaxoSmithKline group of companies in the United States.

TYVERB® is a registered trademark of the GlaxoSmithKline group of companies in Europe.

XELODA® is a registered trademark of Roche Laboratories Inc.

HERCEPTIN® is a registered trademark of Genentech, Inc.

Enquiries:

Onsite Media Enquiries (US Media)

Ken Inchausti

(267) 809 7552

Onsite Media Enquiries (ex-US Media)

Gregory Clarke

(610) 405 0053

UK Media Enquiries:

Philip Thomson

(020) 8047 5502

David Outhwaite

(020) 8047 5502

Stephen Rea

(020) 8047 5502

US Media Enquiries:

Nancy Pekarek

(919) 483 28

Mary Anne Rhyne

(919) 483 2839

Kevin Colgan

(919) 483 2839

Sarah Alspach

(919) 483 2839

European Analyst/Investor Enquiries:

David Mawdsley

(020) 8047 5564

Sally Ferguson

(020) 8047 5543

Gary Davies

(020) 8047 5503

US Analyst/ Investor Enquiries:

Tom Curry

(215) 751 5419

Jen Hill Baxter

(215) 751 7002

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2008.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS